Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Roughly 30,000 Americans are diagnosed with multiple myeloma each year—a rare but serious cancer of the plasma cells. Historically treated with chemotherapy, patients often faced recurring disease and…
Hosted by the American Thoracic Society International Health Committee, respiratory health professionals from the US, South Africa, Kenya, and Nigeria discuss their experiences with COVID-19. Challenges in Africa…
A new multicenter study hopes to ascertain whether the adjuvant implementation of personalized cancer vaccine mRNA-4157, in combination with pembrolizumab, improves recurrence-free survival (RFS) when compared with pembrolizumab…
Trainees Luke J. Rogers, Akshay Patel, and Ruth Benson discuss the CovidSurg database, which includes any patient having an operation who tested positive for COVID-19 prior to or…
A research collaboration between Georgia Tech and Emory University, with funding from the National Institutes of Health and the National Science Foundation, studied the effects of hydroxychloroquine (HCQ)…
A treatment is undergoing development in hopes to receive FDA clearance to be the first drug targeted at the third- and fourth-line space in patients with refractory renal cell carcinoma…
Samuel I. Fink, MD, FACP, internal medicine specialist in private practice in Tarzana, California, and his daughter, Sarrica Fink, RN, previously in practice at Cedar Sinai Medical Center…
Can targeted therapies offer safer and more efficient means to treat patients with acute myeloid leukemia (AML)? Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park…
Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, describes acute myeloid leukemia (AML) and details how emerging targeted treatments are transforming the…
In this interview, Omid Hamid, MD, discusses the current landscape of targeted therapies in melanoma. He shares his thoughts about immune response, triplet therapy, and soon-to-be-released data that…
Mark M. Awad, MD, PhD, assistant professor of Medicine at Harvard Medical School and clinical director of the Thoracic Oncology Treatment Center at Dana-Farber Cancer Institute, shares insights…
